Considering these therapeutic limitations, the selective inhibition of signal transducer and activator of transcription 3 (STAT3) has emerged as a compelling, mechanistically driven strategy for targeted intervention in IBD. The gene discussed is STAT3; the disease is inflammatory bowel disease.